CeleCor Therapeutics, Inc.
DEL MAR, CA · Founded 2017 · CIK 0001705381 · Biotech · Private
Zalunfiban, a subcutaneous GPIIb/IIIa platelet inhibitor for acute myocardial infarction treatment
celecor.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $3.7M
- 3 Form D · Mar 2022
- 55 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 1 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $25,000,000 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $2,700,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1602 | TURTLETREE LABS INC. | — | — |
| 1603 | Maxwell Biosciences, Inc. | — | $11M |
| 1604 | Acer Therapeutics Inc. | — | $8.2M |
| 1605 | CeleCor Therapeutics, Inc. | — | $3.7M |
| 1606 | THERALINK TECHNOLOGIES, INC. | — | $2.6M |
| 1607 | Reglagene, LLC | — | $1.9M |
| 1608 | XenoTherapeutics Corp | — | $1.3M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Peter FinnExecutive Officer
- Robert HillmanDirector · Executive Officer
- Jack LiefDirector
- Andreas RitziDirector
- Caspar SturmDirector
Patents
- RUC-4 Formulationsapplication
- Therapeutic Methodsapplication
- Deuterated RUC-4application
- Deuterated RUC-4granted
- Therapeutic Methodsapplication
- Stable RUC-4 Formulationsapplication
- Deuterated RUC-4application
- Methods For The Administration Of Zalunfibanapplication
- Deuterated RUC-4application
- Methods For The Administration Of Zalunfibanapplication
- Stable RUC-4 Formulationsapplication
- Therapeutic Methodsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.